Geron Stock Surges 95% Following FDA Panel's Favorable Vote on Imetelstat Drug
Friday, 15 March 2024, 15:50
Imetelstat Receives Strong Support from FDA Panel
Geron Corp.'s stock experienced a surge of 95% on Friday, driven by an advisory panel's favorable vote on its blood-disorder drug, Imetelstat. The panel, in a 12-to-2 decision, emphasized that the benefits of the drug outweigh the perceived risks, resulting in a positive outlook for the company's future.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.